Streetbeat News

Revenues

GEN

Gen forecasts its Q4 2024 revenue to be between $960M-$970M, which is below the estimated $974.42M.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:12 pm

AMZN

Amazon reported a year-over-year sales increase across its segments: North American sales grew by 12%, International sales by 11%, and AWS (Amazon Web Services) sales by 13%.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 9:03 pm

QRVO

Analyst ratings for Qorvo (NASDAQ:QRVO) show a mix of opinions, with a recent shift towards a more positive outlook. The average 12-month price target has increased to $114.6, up 7.99% from the previous $106.12. Despite this, Qorvo faces challenges such as lower market capitalization, revenue decline of -4.71% as of September 30, 2023, below-average net margin, ROE, ROA, and a high debt-to-equity ratio. These factors suggest potential financial difficulties ahead.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 9:00 pm

AVB

DHI

EQR

ITB

LEN

REZ

SPY

Mortgage rates decreased last week, offering relief to homeowners and loan applicants after a period of increases. This follows the Federal Reserve's decision not to cut the Fed funds rate in March, contrary to market expectations, which negatively impacted the S&P 500 and the SPDR S&P 500 ETF (SPY). Despite this, homebuilders like D.R. Horton (DHI) and Lennar (LEN) saw stock increases, as did the iShares U.S. Home Construction ETF (ITB). However, residential REITs such as Equity Residential (EQR) and Avalon Bay Communities (AVB) experienced declines, while the iShares Residential and Multisector Real Estate ETF (REZ) saw a slight increase.

Portfolio Pulse from Neil Dennis

February 01, 2024 | 8:07 pm

TGT

Target (NYSE:TGT) has been analyzed by 21 financial analysts, showing a diverse range of perspectives with an average 12-month price target of $146.81, indicating a slight increase from the previous target. The analysis includes various actions by analysts from major firms, reflecting adjustments in ratings and price targets based on market conditions and company performance. Target's financial indicators such as market capitalization, revenue growth, net margin, ROE, and ROA are discussed, highlighting its position in the retail sector.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 8:00 pm

RSG

Five analysts have recently updated their ratings on Republic Services (NYSE:RSG), showing a mix of bullish and bearish sentiments. The average 12-month price target for RSG has been raised to $182.2, indicating a 5.47% increase from the previous target. Analysts from Citigroup, Oppenheimer, Stifel, and Wells Fargo have raised their price targets, reflecting positive market conditions and company performance. Republic Services, a major waste services provider in the US, has shown strong financial performance with a revenue growth rate of 6.34%, a net margin of 12.55%, and above-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 8:00 pm

GOOG

MSFT

NVDA

Microsoft and Alphabet's Google are tapping into India's AI talent pool, with top executives visiting to foster AI adoption. Microsoft's CEO Satya Nadella and Google's chief scientist Jeff Dean are engaging with developers and industry leaders in India. Nvidia also recognizes India's potential in AI, with a significant deal and partnerships enhancing its presence. India's vast programming community and significant contributions to AI projects highlight its pivotal role in global AI innovation.

Portfolio Pulse from Anusuya Lahiri

February 01, 2024 | 7:23 pm

MRK

MRNA

MYNZ

PFE

Pfizer Inc (NYSE:PFE) reported a Q4 revenue drop of over 41% to $14.25 billion, missing Wall Street estimates. Despite a net loss, adjusted earnings exceeded expectations. Pfizer's focus shifts to oncology, with significant investments in cancer treatment, including the acquisition of Seagen. Moderna Inc (NASDAQ:MRNA) and Mainz Biomed N.V. (NASDAQ:MYNZ) also made strides in cancer treatment, with Moderna's skin cancer vaccine showing promising results in combination with Merck & Co Inc's (NYSE:MRK) Keytruda. Mainz Biomed reported high accuracy in colorectal cancer detection with its ColoAlert test. Pfizer aims for $4 billion in annual net cost savings and expects new drugs and business deals to drive future growth.

Portfolio Pulse from Upwallstreet

February 01, 2024 | 7:17 pm

PSX

Four analysts have recently updated their ratings on Phillips 66 (NYSE:PSX), all maintaining a somewhat bullish stance with no changes in the last 30 days. The average 12-month price target for PSX has been raised to $152.00, indicating a 9.95% increase from the previous target of $138.25. Analysts from Wells Fargo, Raymond James, and TD Cowen have raised their price targets, reflecting optimism about the company's future performance. Despite this, Phillips 66 faces challenges with a revenue decline of -11.82% as of September 30, 2023, and below-average net margin, ROE, and ROA, indicating potential profitability and efficiency issues.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 7:01 pm

NTST

Five analysts have recently shared their views on Netstreit Corp (NYSE:NTST), showing a mix of bullish to bearish sentiments. Over the past three months, ratings have shifted, with no changes in the last 30 days. The average 12-month price target for NTST has decreased to $18.00 from $19.33. Analysts from firms like Wolfe Research, Exane BNP Paribas, Keybanc, Truist Securities, and BTIG have updated their ratings and price targets, reflecting various market conditions and company performance. Netstreit, a real estate investment trust, has seen a 30.31% revenue growth but struggles with below-industry net margin, ROE, and ROA, despite a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 7:00 pm